PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.

Mol Cancer Ther · 2024 · PMC11443213 · PMID 38781103

Europe PMC DOI

hedged sentences

0.0620

closest p · 1.2× alpha

0.1100

boldest claim

The sentences

at the margin of statistical significanceP = 0.062so close (0.05 < p ≤ 0.1)

At this time point, a difference in tumor volume was observed between the vehicle group and the combination group at the margin of statistical significance ( P = 0.062).

also in 15 other papers

marginal significanceP < 0.11not close (p > 0.1)

Knocking down the mutant p53 and re-expressing WT p53 in T47D Palbo-R cells reduced synergy with marginal significance ( P < 0.11), but significantly reduced the sensitivity to the combination treatment (Supplementary Fig.

also in 974 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.